BOSTON, Oct. 26, 2021 /PRNewswire/ -- BrickBio, the leader in site specific bioconjugation has launched a collaboration SiteSelect™ Panel for pharmaceutical and drug development partners to streamline ADC site optimization for all linker and payload combinations, delivering another platform to identify higher performing biologics. While validating its chemistries and pipeline, BrickBio has accumulated a diverse data set of proprietary conjugation sites on a reference template used to rapidly screen linker-payloads with varying characteristics such as length, chemistry, and hydrophobicity to identify optimal candidates which have high transferability to partner scaffolds of interest. The ability to rapidly screen linker-payloads with the most versatile conjugation technology will help deliver on the uptick of market demand for the generation of novel conjugates with enhanced therapeutic windows.